CSL Ltd Annual Report 2020

Support for patient communities Our support for patient communities continues as a priority, with the majority of total funding directed towards programs that enhance patient quality of life, protect public health and improve access to our medicines. Some of these strategic programs are detailed following. CSL Behring Bleeding disorders CSL Behring has a deep commitment to global patient communities and has provided product donations to patients in dozens of countries. With more than 30 years of experience treating patients with bleeding disorders, CSL Behring holds its relationship with the World Federation of Hemophilia (WFH) among its strongest partnerships. WFH works to improve the lives of people with haemophilia and other inherited bleeding disorders. As a not-for-profit global network of patient organisations, WFH organises programs that help improve diagnosis and access to care for patients in developing countries, provides medical training, increases awareness, establishes education initiatives and achieves government support through advocacy. Support from longstanding industry partners, such as CSL Behring, helps to deliver these important programs to patients, caregivers and healthcare professionals. CSL Behring continued a partnership with WFH to support critical WFH programs that was renewed for a fourth time in 2019. As a Visionary Corporate Partner, CSL Behring holds a Leadership Partner role in the WFH’s Global Alliance for Progress (GAP) Program that aims to increase the diagnosis and treatment of patients with haemophilia and other bleeding disorders in developing countries. CSL Behring is also a Collaborating Partner of the World Bleeding Disorders Registry (WBDR), the only global registry collecting standardised clinical data on haemophilia patients. CSL Behring continues to be a significant contributor to the WFH Humanitarian Aid Program’s efforts to provide consistent and predictable treatment access through product donations and financial support. As part of its most recent commitment, CSL Behring promised to donate 50 million international units (IUs) of product over a three-year period. In 2019 alone, it we donated almost twice that amount, including both plasma-derived and recombinant therapies, and helped patients in 48 countries. Our partnerships with the WFH and other global patient groups reinforce CSL Behring’s promise to patients by empowering them through education and advocacy, raising awareness, advancing scientific knowledge and improving access to care. Empowering patient communities through education and advocacy Influenza In 2019, Seqirus continued our support for the World Health Organization’s (WHO) Pandemic Influenza Preparedness (PIP) Framework with a corporate contribution. The program aims to improve the sharing of influenza viruses with pandemic potential and the equitable access to products necessary to respond to pandemic influenza (e.g., vaccines, antiviral medicines and diagnostic products). Seqirus has also agreed to donate 10% of influenza vaccine output in real time to WHO for deployment to developing countries in the event of a global pandemic emergency. Commitment to donate 10% of influenza vaccine output in the event of a global pandemic. Snakebite In Papua New Guinea (PNG), the PNG Snakebite Partnership continues to distribute life-saving antivenom across the country. PNG has some of the highest rates of snakebite mortality in the world, caused mainly by taipan and death adder envenomation. The same snake species are found in Australia, where Seqirus antivenom has been in use for decades. The partnership, involving the PNG National Department of Health, the Australian High Commission, Seqirus, the Australian Venom Research Unit, at the University of Melbourne, and the Charles Campbell Toxinology Centre, at the University of Papua New Guinea, significantly improves access to antivenoms by combining a large product donation with healthcare worker training and a purpose-built cold-chain distribution and product management system. Now in the second year of the project, more than 950 vials of antivenom to date have been distributed from the central point in Port Moresby to more than 50 health centres across 12 provinces in PNG. Each vial holding the potential to save a life. 1,275 vials of snake and marine antivenom donated to Papua New Guinea across two years CSL Limited Annual Report 2020 49